Literature DB >> 23649091

Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed.

Inna G Ovsyannikova1, V Shane Pankratz, Robert A Vierkant, Nicholas M Pajewski, Conrad P Quinn, Richard A Kaslow, Robert M Jacobson, Gregory A Poland.   

Abstract

Interindividual variations in vaccine-induced immune responses are in part due to host genetic polymorphisms in the human leukocyte antigen (HLA) and other gene families. This study examined associations between HLA genotypes, haplotypes, and homozygosity and protective antigen (PA)-specific cellular immune responses in healthy subjects following immunization with Anthrax Vaccine Adsorbed (AVA). While limited associations were observed between individual HLA alleles or haplotypes and variable lymphocyte proliferative (LP) responses to AVA, analyses of homozygosity supported the hypothesis of a "heterozygote advantage." Individuals who were homozygous for any HLA locus demonstrated significantly lower PA-specific LP than subjects who were heterozygous at all eight loci (median stimulation indices [SI], 1.84 versus 2.95, P = 0.009). Similarly, we found that class I (HLA-A) and class II (HLA-DQA1 and HLA-DQB1) homozygosity was significantly associated with an overall decrease in LP compared with heterozygosity at those three loci. Specifically, individuals who were homozygous at these loci had significantly lower PA-specific LP than subjects heterozygous for HLA-A (median SI, 1.48 versus 2.13, P = 0.005), HLA-DQA1 (median SI, 1.75 versus 2.11, P = 0.007), and HLA-DQB1 (median SI, 1.48 versus 2.13, P = 0.002) loci, respectively. Finally, homozygosity at an increasing number (≥ 4) of HLA loci was significantly correlated with a reduction in LP response (P < 0.001) in a dose-dependent manner. Additional studies are needed to reproduce these findings and determine whether HLA-heterozygous individuals generate stronger cellular immune response to other virulence factors (Bacillus anthracis LF and EF) than HLA-homozygous subjects.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23649091      PMCID: PMC3697592          DOI: 10.1128/IAI.00269-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Genetic prediction of nonresponse to hepatitis B vaccine.

Authors:  C A Alper; M S Kruskall; D Marcus-Bagley; D E Craven; A J Katz; S J Brink; J L Dienstag; Z Awdeh; E J Yunis
Journal:  N Engl J Med       Date:  1989-09-14       Impact factor: 91.245

2.  Extinction of the human leukocyte antigen homozygosity effect after two doses of the measles-mumps-rubella vaccine.

Authors:  Jennifer L St Sauver; Neelam Dhiman; Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; V Shane Pankratz; Steven J Jacobsen; Gregory A Poland
Journal:  Hum Immunol       Date:  2005-07       Impact factor: 2.850

3.  HLA class II alleles and measles virus-specific cytokine immune response following two doses of measles vaccine.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Jenna E Ryan; Robert A Vierkant; V Shane Pankratz; Steven J Jacobsen; Gregory A Poland
Journal:  Immunogenetics       Date:  2005-01-27       Impact factor: 2.846

4.  Heterozygote advantage for HLA class-II type in hepatitis B virus infection.

Authors:  M R Thursz; H C Thomas; B M Greenwood; A V Hill
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

5.  HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection.

Authors:  J Tang; C Costello; I P Keet; C Rivers; S Leblanc; E Karita; S Allen; R A Kaslow
Journal:  AIDS Res Hum Retroviruses       Date:  1999-03-01       Impact factor: 2.205

6.  The contribution of HLA class I antigens in immune status following two doses of rubella vaccination.

Authors:  Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland
Journal:  Hum Immunol       Date:  2004-12       Impact factor: 2.850

7.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

Authors:  M Carrington; G W Nelson; M P Martin; T Kissner; D Vlahov; J J Goedert; R Kaslow; S Buchbinder; K Hoots; S J O'Brien
Journal:  Science       Date:  1999-03-12       Impact factor: 47.728

8.  Associations between human leukocyte antigen homozygosity and antibody levels to measles vaccine.

Authors:  Jennifer L St Sauver; Inna G Ovsyannikova; Robert M Jacobson; Steven J Jacobsen; Robert A Vierkant; Daniel J Schaid; V Shane Pankratz; Erin M Green; Gregory A Poland
Journal:  J Infect Dis       Date:  2002-05-09       Impact factor: 5.226

9.  Human T cells recognize mycobacterial heat shock proteins in the context of multiple HLA-DR molecules: studies with healthy subjects vaccinated with Mycobacterium bovis BCG and Mycobacterium leprae.

Authors:  A S Mustafa; K E Lundin; F Oftung
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

10.  Influence of HLA-DRB1 alleles on lymphoproliferative responses to a naturally processed and presented measles virus phosphoprotein in measles immunized individuals.

Authors:  Inna G Ovsyannikova; Gregory A Poland; Nathan J Easler; Robert A Vierkant
Journal:  Hum Immunol       Date:  2004-03       Impact factor: 2.850

View more
  11 in total

Review 1.  Adversomics: a new paradigm for vaccine safety and design.

Authors:  Jennifer A Whitaker; Inna G Ovsyannikova; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2015-05-02       Impact factor: 5.217

2.  HLA alleles associated with the adaptive immune response to smallpox vaccine: a replication study.

Authors:  Inna G Ovsyannikova; V Shane Pankratz; Hannah M Salk; Richard B Kennedy; Gregory A Poland
Journal:  Hum Genet       Date:  2014-06-01       Impact factor: 4.132

Review 3.  Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.

Authors:  Gregory A Poland; Richard B Kennedy; Brett A McKinney; Inna G Ovsyannikova; Nathaniel D Lambert; Robert M Jacobson; Ann L Oberg
Journal:  Semin Immunol       Date:  2013-06-05       Impact factor: 11.130

4.  A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens, Bacillus anthracis and Yersinia pestis.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Michelle L Kirtley; Eric C Fitts; Jourdan A Andersson; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  Front Immunol       Date:  2017-06-26       Impact factor: 7.561

5.  RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.

Authors:  C M Nielsen; J Vekemans; M Lievens; K E Kester; J A Regules; C F Ockenhouse
Journal:  Vaccine       Date:  2018-02-10       Impact factor: 3.641

6.  A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague.

Authors:  Pan Tao; Marthandan Mahalingam; Jingen Zhu; Mahtab Moayeri; Jian Sha; William S Lawrence; Stephen H Leppla; Ashok K Chopra; Venigalla B Rao
Journal:  mBio       Date:  2018-10-16       Impact factor: 7.867

7.  Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination.

Authors:  Sara Pischedda; Daniel O'Connor; Benjamin P Fairfax; Antonio Salas; Federico Martinon-Torres; Andrew J Pollard; Johannes Trück
Journal:  Clin Epigenetics       Date:  2021-02-04       Impact factor: 6.551

Review 8.  Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Authors:  Jarad M Schiffer; Michael M McNeil; Conrad P Quinn
Journal:  Expert Rev Vaccines       Date:  2016-03-25       Impact factor: 5.683

Review 9.  Personalized vaccinology: A review.

Authors:  G A Poland; I G Ovsyannikova; R B Kennedy
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 4.169

Review 10.  Current Challenges in Vaccinology.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Peter Palese; Gregory A Poland
Journal:  Front Immunol       Date:  2020-06-25       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.